Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ecco-jcc/jjx168 | DOI Listing |
Publication Analysis
Top Keywords
corrigendum exposure-efficacy
4
exposure-efficacy relationships
4
relationships vedolizumab
4
vedolizumab induction
4
induction therapy
4
therapy patients
4
patients ulcerative
4
ulcerative colitis
4
colitis crohn's
4
crohn's disease
4
Similar Publications
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
J Crohns Colitis
March 2018
Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!